Option chain shows key data for BioInvent International's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioInvent International.

BioInvent International (OTC:BOVNF) Stock, Option Chain

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

Biotech

News

Penny Stocks

Health Care

Contracts

General

BOVNF

EXEL

Exelixis-BioInvent Establish Immuno-Oncology Pact

Small Cap

Movers

Trading Ideas

CASI

Casi Pharma-Partnered BioInvent&#39;s Lead Cancer Program Gets FDA Orphan Drug Tag

BIOINVENT INTL NEW by Bioinvent International AB

BioInvent International AB

BioInvent International reports Q2 results

BioInvent International AB ( ($BOVNF) ) has released its Q3 earnings. Here is a breakdown of the information BioInvent International AB presented t...

BioInvent Reports Q3 2024 Progress in Antibody Development

BioInvent International

Comments

BioInvent International

BioInvent International (BOVNF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga